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Abstract. The reaction of 9.10-diaminophenanthrene with
[{Rh(μ-Cl)(ptpy)2}2] yields – quite unexpected – the new cyclomet-
alated complex salts [Rh(ptpy)2(9,10-diiminophenanthrene)]PF6 (1),
whereas with the corresponding dinuclear iridium compound the
“usual” [Ir(ptpy)2(9,10-diaminophenanthrene)]PF6 (2) is obtained. The
Introduction
Bis-cyclometalated IrIII complexes play an important role in
the development of modern optoelectronic technologies (e.g.
organic light-emitting diodes – OLEDs and light-emitting elec-
trochemical cells – LEECs), biological labels, and chemical
sensors.[1–3] Recently also many studies were devoted towards
therapy of cancers due to the high cytotoxic activities of many
of these compounds.[4] Our group’s long-time interest in cyclo-
metalated MIII complexes (M = Rh, Ir), triggered also a study
of the cytotoxic properties of heteroleptic cationic
[M(N∧C)2(N∧N)]+ complexes with ancillary ligands N∧N of
the substituted bipyridine or phenanthroline type.[5] 9,10-Di-
aminophenanthrene (“pham”) and its oxidation product 9,10-
diiminophenanthrene (“phim”) appear structurally related to
the phenanthroline ligands already studied by us, which is im-
portant in view of the known anti-cancer activity of the
“metallointercalators” based on RhIII complexes with this and
closely related diimino ligands.[6]
In this communication we describe the synthesis, characteri-
zation, and the evaluation of the biological properties of two
new cyclometalated complex salts [M(C∧N)2(L)]PF6 (M = Rh,
L = 9,10-diiminophenanthrene; M = Ir, L = 9,10-diaminophen-
anthrene).
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molecular structure of compound 1 was confirmed by single-crystal
X-ray diffraction. 1 crystallized in the monoclinic space group
P21/n as a dichloromethane solvate. Both compounds display signifi-
cant cytotoxicity against human cancer cell lines with the IC50 values
in the low micromolar range.
Results and Discussion
The preparation of the cationic mononuclear title complexes
started by cleavage of the dimeric precursor compounds
[{M(μ-Cl)(ptpy)2}2] (M = Rh, Ir; ptpy = 2-para-tolyl-pyrid-
inato) by the chelating 9,10-diaminophenanthrene ligand in a
refluxing mixture of dichloromethane / methanol. The thus
formed chloride salts [M(C∧N)2(L)]Cl yielded after metathesis
with KPF6 the corresponding hexafluorophosphate salts which
were obtained as red-brown powders (Scheme 1). The new
complexes were characterized by elemental analysis, 1H and
13C NMR spectroscopy, mass spectrometry, infrared and UV/
Vis spectroscopy. Moreover, for 1 a single-crystal X-ray dif-
fraction study was undertaken.
The 1NMR spectrum of the rhodium compound 1 in CD2Cl2
is characterized by the presence of a low-field singlet at δ =
11.19 ppm, which is absent in the spectrum of the iridium com-
plex 2. This signal is reminiscent of the = NH proton signals
of the above-mentioned “phim” complexes.[6] Examination of
the mass spectra of both compounds shows that the molecular
peak in 1 corresponds to the formula [Rh(ptpy)2(phim)]+ com-
plex, while in 2 a formula [Ir(ptpy)2(pham)]+ can be derived.
Thus it can be concluded that a primarily formed rhodium
complex of “pham” had been oxidized by air to the final com-
pound 1. This result is fully analogous to the earlier observa-
tion that the reaction of [Rh(phpy)2Cl]2 with “pham” leads to
isolation of [Rh(phpy)2(phim)]+ salts.[6b] This “non-innocent”
redox behavior of the “pham”/“phim” system has also been
observed with RhI and RuII complexes.[7,8]
The UV/Vis-absorption spectrum of the rhodium complex 1
was recorded in dichloromethane. The spectrum of 1 showed
bands at 245, 256, 268, 289, and 305 nm, respectively, which
could be assigned to spin-allowed (IL) (π  π*)(ptpy) transi-
tions. The band at 368 and 433 nm corresponds to a 1MLCT
[dπ(Rh)  π*(ptpy)] transition. The UV/Vis-absorption spec-
trum of the iridium complex 2 was also recorded in dichloro-
methane. The spectrum of 2 showed bands at 258 and 310 nm,
respectively, which could be assigned to spin-allowed (IL)
Journal of Inorganic and General Chemistry
Zeitschrift für anorganische und allgemeine Chemie
ARTICLE
Scheme 1. Synthesis of 1 and 2.
(π π*) (ptpy) transitions. The band at 393, 468 and 504 nm
corresponds to a 1MLCT [dπ(Ir)  π*(ptpy)] transition.
We were able to obtain red- brown single crystals of com-
pound 1 suitable for X-ray diffraction. 1 crystallizes in the
monoclinic space group P21/n as a bis-dichloromethane solv-
ate. A selected view of the cation of 1 is shown in Figure 1.
Table 1 lists selected bond lengths and angles in comparison
with two other rhodium-“phim” complexes. 1 exhibits two cy-
clometalated 2-(p-tolyl)pyridinato ligands in the usual trans
N,N configuration and one 9,10-diiminophenanthrene ligand
in pseudooctahedral coordination.
Figure 1. Molecular structure of the cation of 1 in the crystal (ORTEP
drawing and atom labeling scheme with 30% probability level).
The Rh–N and Rh–C bond parameters within the cyclo-
metallating chelate rings have the usually observed values. The
long C1–C14 bond together with the short C1–N1 and C14–
N2 bonds clearly proof the diiminophenanthrene nature of the
ancillary ligand. Somewhat surprising is the relatively large
asymmetry in the bonding of the two imino nitrogen atoms to
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Table 1. Important bond lengths /Å and angles /° in 1 and two related
compounds.
1 [Rh(phpy)2(phi)]Cl [Rh(en)2(phi)]Br3
[6b] [9]
Rh–Nphim 2.168(2), 2.153(2), 2.122(2) 1.996(15),
2.115(2) 2.007(14)
Rh–N(N∧C) 2.047(1), 2.033(2), 2.043(2) –
2.038(2)
Rh–C(N∧C) 2.010(2), 2.003(2), 1.996(3) –
1.985(2)
C=NH 1.292(2), 1.300(3), 1.281(3) 1.29(2), 1.28(2)
1.290(2)
C1–C14 1.498(2) 1.487(3) 1.45(2)
(NRhC)(N∧C) 80.99(6), 80.66(9), 80.79(9) –
81.22(7)
(NRhN)phim 73.40(6) 73.92(8) 77.1(6)
the central rhodium atom, which differ by 0.053(2) Å, whereas
in the closely related bis(phenylpyridinato) complex this dif-
ference is only 0.031(2) Å and in the bis(ethylenediamine)
complex this difference is even smaller [0.011(15) Å].
Organometallic IrIII and RhIII compounds containing bis-aryl
ligands attracted considerable attention as potential candidates
for the rational design of novel metal-based anti-cancer drugs.
In recent years, we examined different series of 2-(p-tolyl)pyr-
idine-containing Ir and Rh complexes for their in vitro cyto-
toxicity and demonstrated the modulating effects of selected
ancillary bidentate aromatic ligands.[5] To continue our efforts
in establishing detailed structure-activity relationships for this
promising compound class, complexes 1 and 2 were subjected
to an MTT assay probing the in vitro antiproliferative activity
on the representative two human cancer cell lines HT-29 (colo-
rectal adenocarcinoma) and MCF-7 (breast adenocarcinoma)
(see Table 2).
Both complexes show a high activity against both tested cell
lines reaching IC50 values of 0.6 μM (1) and 1.4 μM (2)
against HT-29 as well as 0.7 μM (1) and 0.9 μM (2) against
MCF-7 respectively. In direct comparison to cisplatin, the ac-
tivity of the complexes is significantly increased (factor 10 on
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Table 2. IC50 values in μM of 1 and 2 for the antiproliferative effects
in MCF-7 and HT-29 cells.
IC50 /μM
HT-29 MCF-7
1 0.60.1 0.70.2
2 1.40.2 0.90.2
Cisplatin 9.90.5 23.00.6
HT-29 and approximately factor 20 against MCF-7). Thus, the
presented complexes are comparable to the most active com-
plexes tested in our recent works. It is evident that the substitu-
tion neither of the metal cation nor the oxidation state of the
bidentate imine/amine ligand seems to negatively affect the
overall activity, which might be explained by a similar mode
of action that is not disturbed by the introduced structural
changes. In view of the results of Barton et al., who showed
specific interactions of related RhIII complexes with DNA, es-
pecially DNA base-pair mismatches,[10] it can be assumed that
one influencing factor for the mode of action of 1 and 2 is the
ability to intercalate into DNA. The overall efficiency is fur-
ther controlled by the cellular uptake, which crucially depends
on the solubility and lipophilicity of the complexes. Further
studies concerning these factors are envisioned for the most
active complexes published by our group in recent years.
Conclusions
The synthesis and characterization of the new bis-cyclomet-
alated cationic complex salts [Rh(ptpy)2(9.10-diiminophenan-
threne)]PF6 (1) and [Ir(ptpy)2(9.10-diaminophenanthrene)]PF6
(2) were reported and their biological activities were investi-
gated. The compounds exhibit cytotoxic effects towards two
cell lines (HT29 and MCF-7). For 1 and 2 high activities were
observed, providing IC50 values in the low micromolar range
and an approximately tenfold increase in activity compared to
cisplatin. Furthermore, the crystal and molecular structure of
the new compound 1 was confirmed by X-ray crystal structure
determination.
Experimental Section
General: All manipulations were performed under an atmosphere of
dry nitrogen using conventional Schlenk techniques. 9,10-Diami-
nophenanthrene was purchased from Alfa Aesar and used as received.
[{M(μ-Cl)(C∧N)2}2] (M = Rh, Ir) were prepared by adequately modi-
fied literature methods.[3a,3b] NMR spectra were usually recorded in
CD2Cl2 using a Jeol Eclipse 400 instrument operating at 400 MHz
(1H) and 100 MHz (13C) respectively. Chemical shifts are given in
ppm, referenced to the solvent signals at δ = 5.30 (1H) or 53.8 ppm
(13C). Mass spectra were measured using a JeolMstation JMS 700
spectrometer. IR spectra were recorded as KBr pellets on a Bruker IFS
66v/S spectrometer. UV/Vis spectra were obtained on a Cary 50 Bio
UV/Vis spectrophotometer. Elemental analyses (C, H, N) were per-
formed by the Microanalytical Laboratory of the Department of Chem-
istry, LMU Munich, using a Heraeus Elementar Vario EL instrument.
Biological Activities: Dulbecco’s Modified Eagle’s Medium
(DMEM), containing 10% fetal calf serum, 1% penicillin and strepto-
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mycin, was used as growth medium. MCF-7 and HT-29 cells were
detached from the wells with trypsin and EDTA, harvested by centrifu-
gation and resuspended again in the cell culture medium. The assays
were carried out on 96 well plates with 6000 (3000) cells per well for
MCF-7 (HT-29, respectively). After 24 h of incubation at 37 °C and
10% CO2, the cells were treated with the compounds 1 and 2 (with
DMSO concentrations of 0.5%) with a final volume of 200 μL per
well. For a negative control, one series of cells was left untreated.
The cells were incubated for 48 h followed by adding 50 μL MTT
(2.5 mg·mL–1). After an incubation time of 2 h, the medium was re-
moved and 200 μL DMSO were added. The formazan crystals were
dissolved and the absorption was measured at 550 nm, using a refer-
ence wavelength of 620 nm. Each test was repeated in quadruplicates
in two independent experiments for each cell line. IC50 values for
cisplatin were determined under identical conditions.
Synthesis of 1 and 2: To a solution of [{M(μ-Cl)(ptpy)2}2] (M = Rh,
Ir) (0.15 mmol) in 25 mL of a mixture of CH2Cl2/MeOH (3:1) the
ligand 9,10-diaminophenanthrene (0.3 mmol) was added and the mix-
ture refluxed with stirring for 2 h. After cooling to room temperature
KPF6 (0.5 mmol) was added and stirred for 20 min. The solvent was
removed to dryness in vacuo and the residue dissolved in dichloro-
methane and chromatographed on alumina with CH2Cl2/acetone (9:1)
as the eluent. The resulting solution was evaporated to dryness, the
residue was redissolved in 5 mL of dichloromethane, and the product
was precipitated by slow diffusion of methanol and n-hexane.
[Rh(ptpy)2(9,10-diiminophenanthrene)]PF6 (1): Yield: 80 mg
(33.7%). C38H30N4F6PRh: calcd. C, 57.73; H, 3,83; N, 7.07 %; found:
C, 57.82; H, 4.21; N, 6.97%. MS (FAB+): m/z = 645.7 [M]+ complex
cation. 1H NMR: δ = 11.19 (2 H, NH), 8.27 (d, 8 Hz, 2 H, H6), 8.06
(d, 7 Hz, 2 H, H3), 8.02–7.78 (m, 8 H, H4+Hphim), 7.67 (d, 8 Hz, 2 H,
H8), 7.60 (t, 8 Hz, 2 H, Hphim), 7.13 (m, 2 H, H5), 6.94(d, 6 Hz, 2 H,
H9), 6.06 (s, 2 H, H11), 2.11 (s, 6 H, CH3). 1H NMR (400 MHz,
CD3OD): δ = 8.36 (d, 8 Hz, 2 H, H6), 8.30 (dd, J = 8/1.2 Hz, 2 H,
Hphim), 8.11–8.08 (m, 4 H, H3+H4), 7.98 (ddd, J = 8/7/1.6 Hz, 2 H,
Hphim), 7.79 (ddd, J = 8/7/1.3 Hz, 2 H, Hphim), 7.75 (d, J = 8 Hz, 2 H,
H8), 7.56 (ddd, J = 8/7/1.0 Hz, 2 H, Hphim), 7.20 (ddd, J = 7/6/1.5 Hz,
2 H, H5), 6.89 (ddd, J = 8/1.7/0.7 Hz, 2 H, H9), 6.06 (s, 2 H, H11),
2.05 (s, 6 H, CH3). 13C{1H} NMR: δ = 168.9 (C=NH), 166.0 (d, JRh-
C = 28.5 Hz, C12), 165.8 (C2), 150.7 (C6), 141.5/ 141.1 (C7+C10),
138.9 (C4), 136.0 (Cphim), 133.8 (C11), 130.6 (Cphim), 126.5 (C8),
126.0 (Cphim), 125.7 (C9), 125.3/124.9 (Cphim), 123.6 (C5), 120.2 (C3),
22.2 (CH3). IR (KBr) ν˜ = 3343 w,br, 3300 w,br, 3035 w, br, 2915 w,br,
2863 w,br, 1603 s, 1588 s, 1563 m, 1481 s, 1462 s, 1451 s, 1428 m,
1387 s, 1315 m, 1270 w, 1241 w, 1209 w, 1163 m, 1138 w, 1064 w,
1033 w, 957 w, 841 vs, br, 773 m, 755 w, 714 w, 677 w, 617 w, 557
s, 525 m, 513 w, 469 w, 429 w cm–1. UV/Vis (0.025 mM, CH2Cl2): λ
(nm) = 245 (60.000), 256 (58.280), 268 (59.400), 289 (37.840), 305
(21.960), 368 (12.960), 433 (12.900).
[Ir(ptpy)2(9,10-diaminophenanthrene)]PF6 (2): Yield: 90 mg
(34%). C38H32N4F6PIr: calcd. C, 51.75; H, 3.66; N, 6.35%; found: C,
51.44; H, 3.73; N, 6.16%. MS (FAB+): m/z = 735.8 [M + H]+. 1H
NMR: δ = 8.32 (d, 8 Hz, 2 H, H6), 8.25–8.10 (m, 2 H, NH2?) 7.92
(d, J = 8 Hz, 2 H, H3), 7.88 (d, J = 6 Hz, 2 H, Hphim), 7.81 (ddd, J =
8/7/1.5 Hz, 2 H, H4), 7.69 (d, J = 8 Hz, 2 H, H8), 7.63 (t, J = 7.5 Hz,
2 H, Hphim), 7.06 (m, 2 H, H5), 6.87 (ddd, J = 8/1.7/0.6 Hz, 2 H, H9),
6.02 (s, 2 H, H11) 2.12 (s, 6 H, CH3). 13C{1H} NMR: δ = 170.7
(CNH?), 168.4 (C2), 152.0 (C6?), 149.5 (C12?), 141.6/ 141.5
(C7+C10), 138.9 (C4), 136.1/ 133.9 (Cphim) 132.9 (C11), 130.1
(2Cphim), 126.3 (C8), 125.6/125.4/125.1 (C9+3Cphim), 123.7 (C5),
120.0 (C3), 22.1 (CH3). IR (KBr) ν˜ = 3343 w,br, 3305 w,br, 3037
w,br, 2918 w,br, 2862 w,br, 1603 s, 1590 s, 1563 m, 1479 s, 1463 s,
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1452 s, 1428 w, 1398 s, 1318 m, 1269 w, 1242 w, 1222 w, 1163 m,
1137 w, 1066 w, 1036 w, 957 w, 846 vs,br, 770 m, 757 w, 717 w, 679
w, 615 w, 557 s, 528 m, 514 w, 452 w, 426 w cm–1. UV/Vis
(0.025 mM, CH2Cl2) λ (nm) = 258 (75.200), 310 (27.200), 393
(10.560), 468 (17.920), 504 (15.129).
Crystal Structure Determination and Refinement: A suitable crystal
for X-ray diffraction of 1 was obtained from dichloromethane/MeOH/
n-hexane solution. The crystal was selected by means of a polarization
microscope, mounted on the tip of a glass fiber, and investigated at
100 K with a Bruker D8 venture TXS diffractometer using Mo-Kα
radiation (λ = 0.71073 Å). The structures were solved by SHELXT[11]
and refined by full-matrix least-squares calculations on F2 (SHELXL-
2014/7).[12] Anisotropic displacement parameters were refined for all
non-hydrogen atoms. Details of the crystal data, data collection, struc-
ture solution, and refinement parameters of compound 1 are summa-
rized in Table 3.
Table 3. Experimental data for the crystal structure determination
of 1.
[Rh(ptpy)2(9,10-
diiminophenanthrene)]PF6 (1)
Empirical formula C40H34Cl4F6N4PRh
Formula weight 960.39
Temperature /K 100(2)
Crystal system monoclinic
Space group P21/n
Unit cell dimensions
a /Å 14.6641(4)
b /Å 16.9956(5)
c /Å 15.6241(4)
ß /° 101.0760(10)
Volume /Å3 3821.39(18)
Z 4
ρ calcd. /g·cm–3 1.669
μ (Mo-Kα) /mm–1 0.835
F(000) 1936
Crystal size /mm3 0.10.080.03
Θ-range 2.784 to 30.522°.
Index ranges –20  h  20, –24  k  24,
–22  l = 22
Reflections collected 70682
Independent reflections 11653 [R(int) = 0.0373]
Absorption correction Semi-empirical from equivalents
Max. and min. transmission 0.7461 and 0.7137
Data / parameters 11653 / 515
Goodness-of-fit on F2 1.012
Final R indices [I  2σ(I)] R1 = 0.0295, wR2 = 0.0732
R indices (all data) R1 = 0.0367, wR2 = 0.0777
Largest diff. peak and hole /e·Å–3 1.478 and –1.188
Crystallographic data (excluding structure factors) for the structure in
this paper have been deposited with the Cambridge Crystallographic
Data Centre, CCDC, 12 Union Road, Cambridge CB21EZ, UK. Copies
of the data can be obtained free of charge on quoting the depository
number CCDC-1938428 (1) (Fax: +44-1223-336-033; E-Mail:
deposit@ccdc.cam.ac.uk, http://www.ccdc.cam.ac.uk)
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